Bulletin
Investor Alert

Merck & Co. Inc.

NYS: MRK

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 9, 2022, 7:58 p.m.

MRK
/zigman2/quotes/209956077/composite

$

108.78

Change

0.00 0.00%

Volume

Volume 577,485

Quotes are delayed by 20 min

/zigman2/quotes/209956077/composite

Previous close

$ 110.85

$ 108.78

Change

-2.07 -1.87%

Day low

Day high

$108.75

$111.37

Open

52 week low

52 week high

$71.97

$111.37

Open

Company Description

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human ...

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Valuation

P/E Current

21.56

P/E Ratio (with extraordinary items)

18.47

P/E Ratio (without extraordinary items)

14.91

Price to Sales Ratio

3.98

Price to Book Ratio

5.07

Price to Cash Flow Ratio

13.79

Enterprise Value to EBITDA

18.22

Enterprise Value to Sales

5.13

Efficiency

Total Asset Turnover

0.50

Liquidity

Current Ratio

1.27

Quick Ratio

1.02

Cash Ratio

0.34

Profitability

Gross Margin

72.47

Operating Margin

27.94

Pretax Margin

28.38

Net Margin

25.24

Return on Assets

12.52

Return on Equity

38.88

Return on Total Capital

20.75

Capital Structure

Total Debt to Total Assets

32.77

Officers and Executives

Name Age Officer Since Title
Mr. Robert M. Davis 54 2014 Chief Financial Officer & Executive Vice President
Ms. Caroline A. Litchfield - 1990 Treasurer
Mr. Dave Williams - - Chief Information & Digital Officer
Mr. Sanat Chattopadhyay - - EVP & President-Merck Manufacturing Division
Dr. Dean Y. Li 58 2017 Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/10/2022 Steven C. Mizell
EVP, Chief HR Officer
15,000   Disposition at $101.42 per share. 1,521,300
11/10/2022 Steven C. Mizell
EVP, Chief HR Officer
15,000   Derivative/Non-derivative trans. at $0 per share. 0
11/09/2022 Robert M. Davis
CEO & President; Director
100   Disposition at $103.59 per share. 10,359
11/09/2022 Robert M. Davis
CEO & President; Director
79,918   Disposition at $102.98 per share. 8,229,955
11/09/2022 Robert M. Davis
CEO & President; Director
87,595   Disposition at $101.94 per share. 8,929,434
11/09/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
1,795   Disposition at $103.21 per share. 185,261
11/09/2022 Robert M. Davis
CEO & President; Director
167,613   Derivative/Non-derivative trans. at $0 per share. 0
11/08/2022 Steven C. Mizell
EVP, Chief HR Officer
20,000   Disposition at $101 per share. 2,020,000
11/08/2022 Steven C. Mizell
EVP, Chief HR Officer
20,000   Derivative/Non-derivative trans. at $0 per share. 0
11/07/2022 Kenneth C. Frazier
Executive Chair; Director
84,721   Disposition at $100.07 per share. 8,478,030
11/07/2022 Kenneth C. Frazier
Executive Chair; Director
126,134   Disposition at $99.42 per share. 12,540,242
11/07/2022 Kenneth C. Frazier
Executive Chair; Director
24,914   Disposition at $98.45 per share. 2,452,783
11/07/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
45,561   Disposition at $99.47 per share. 4,531,952
11/07/2022 Kenneth C. Frazier
Executive Chair; Director
235,769   Derivative/Non-derivative trans. at $0 per share. 0
11/07/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
7,045   Derivative/Non-derivative trans. at $0 per share. 0
11/07/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
13,540   Derivative/Non-derivative trans. at $0 per share. 0
11/07/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
17,455   Derivative/Non-derivative trans. at $0 per share. 0
11/07/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
14,703   Derivative/Non-derivative trans. at $0 per share. 0
11/04/2022 Kenneth C. Frazier
Executive Chair; Director
34,810   Disposition at $99.08 per share. 3,448,974
11/04/2022 Kenneth C. Frazier
Executive Chair; Director
200,190   Disposition at $98.53 per share. 19,724,720
11/04/2022 Kenneth C. Frazier
Executive Chair; Director
235,000   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2022 Kenneth C. Frazier
Executive Chair; Director
20,383   Disposition at $99.09 per share. 2,019,751
11/03/2022 Kenneth C. Frazier
Executive Chair; Director
214,617   Disposition at $98.68 per share. 21,178,405
11/03/2022 Kenneth C. Frazier
Executive Chair; Director
235,000   Derivative/Non-derivative trans. at $0 per share. 0
11/02/2022 Kenneth C. Frazier
Executive Chair; Director
94,339   Disposition at $100.4 per share. 9,471,635
11/02/2022 Kenneth C. Frazier
Executive Chair; Director
205,661   Disposition at $99.68 per share. 20,500,288
11/02/2022 Kenneth C. Frazier
Executive Chair; Director
134,172   Derivative/Non-derivative trans. at $0 per share. 0
11/02/2022 Kenneth C. Frazier
Executive Chair; Director
165,828   Derivative/Non-derivative trans. at $0 per share. 0
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
1,470   Gift at $0 per share. 0
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
2,450   Gift at $0 per share. 0
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
1,710   Gift at $0 per share. 0
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
700   Disposition at $101.05 per share. 70,735
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
96,981   Disposition at $100.22 per share. 9,719,435
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
202,319   Disposition at $99.61 per share. 20,152,995
11/01/2022 Kenneth C. Frazier
Executive Chair; Director
300,000   Derivative/Non-derivative trans. at $0 per share. 0
10/31/2022 Kenneth C. Frazier
Executive Chair; Director
229,302   Disposition at $101.03 per share. 23,166,381
10/31/2022 Kenneth C. Frazier
Executive Chair; Director
70,698   Disposition at $99.82 per share. 7,057,074
10/31/2022 Kenneth C. Frazier
Executive Chair; Director
300,000   Derivative/Non-derivative trans. at $0 per share. 0
10/30/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
450   Derivative/Non-derivative trans. at $100.77 per share. 45,346
10/30/2022 Johannes Jacobus Oosthuizen
President, U.S. Market
913   Derivative/Non-derivative trans. at $100.77 per share. 92,003
/news/latest/company/us/mrk

MarketWatch News on MRK

  1. McCormick, PulteGroup, and Merck Boost Dividends

    7:30 a.m. Dec. 3, 2022

    - Lawrence C. Strauss

  2. What Bear Market? The Dow Is Down Just Over 5% in 2022. 

    2:26 p.m. Dec. 1, 2022

    - Jacob Sonenshine

  3. Dividend Stocks Are for Choppy Times. Stay Afloat.

    9:30 a.m. Dec. 1, 2022

    - Lawrence C. Strauss

  4. Why the Worst Could Be Over for Stocks

    7:53 p.m. Nov. 25, 2022

    - Andrew Bary

  5. Johnson & Johnson stock rises Wednesday, still underperforms market

    4:32 p.m. Nov. 23, 2022

    - MarketWatch Automation

  6. Johnson & Johnson stock rises Tuesday, still underperforms market

    4:32 p.m. Nov. 22, 2022

    - MarketWatch Automation

  7. U.S. stocks finish lower as China COVID-19 fears resurface

    4:32 p.m. Nov. 21, 2022

    - Vivien Lou Chen

  8. Merck buying Imago BioSciences in $1.3 billion deal.

    1:22 p.m. Nov. 21, 2022

    - Angela Palumbo

  9. Merck to buy Imago BioSciences in a deal valued at $1.35 bln

    6:47 a.m. Nov. 21, 2022

    - Tomi Kilgore

  10. Johnson & Johnson stock rises Friday, outperforms market

    4:32 p.m. Nov. 18, 2022

    - MarketWatch Automation

  11. Johnson & Johnson stock outperforms competitors on strong trading day

    4:32 p.m. Nov. 17, 2022

    - MarketWatch Automation

  12. Johnson & Johnson stock rises Wednesday, outperforms market

    4:32 p.m. Nov. 16, 2022

    - MarketWatch Automation

  13. Johnson & Johnson stock rises Tuesday, still underperforms market

    4:32 p.m. Nov. 15, 2022

    - MarketWatch Automation

  14. Loading more headlines...
/news/nonmarketwatch/company/us/mrk

Other News on MRK

  1. The Biotech Takeout Menu Gets Pricier

    7:30 a.m. Dec. 8, 2022

    - David Wainer

  2. What You Should Know About Treating Covid-19

    3:31 p.m. Dec. 7, 2022

    - Jared S. Hopkins

  3. Moderna Heads Into 2023 With Several Irons in the Fire

    9:14 a.m. Dec. 7, 2022

    - GuruFocus.com

  4. GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe

    10:36 a.m. Dec. 5, 2022

    - Zacks.com

  5. Should Investors Consider These 3 Low-Beta Stocks?

    6:23 p.m. Dec. 2, 2022

    - Zacks.com

  6. Loading more headlines...

At a Glance

Merck & Co., Inc.

2000 Galloping Hill Road

Kenilworth, New Jersey 07033

Phone

1 9087404000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$48.91B

Net Income

$12.35B

Employees

68,000

/news/pressrelease/company/us/mrk

Press Releases on MRK

  1. Recession Proof Stocks In Focus (MASN,RXDX,SMMT,XOM,RNAZ)

    9:22 a.m. Dec. 8, 2022

    - Investor Brand Media

  2. Merck MRK Trading Report

    4:47 a.m. Dec. 8, 2022

    - Stock Traders Daily

  3. Dow Movers: AAPL, MRK

    10:12 a.m. Dec. 7, 2022

    - MarketNewsVideo.com

  4. Loading more headlines...
Link to MarketWatch's Slice.